AstraZeneca demonstrates positive early results from its trial evaluating COVID-19 vaccine-AZD1222
In a frenzied race to find a global cure for COVID-19, several pharma players are testing waters and presenting results from clinical studies evaluating their potential candidates.
Not long after, Moderna, a US biotech, presented early results of its vaccine candidate m1273, drugmaker AstraZeneca has released early results of its COVID-19 vaccine, AZD1222, developed by Oxford University.
According to the study published in the Lancet, the vaccine was able to produce neutralizing antibodies and immune T-cells to tackle SARS-CoV-2. The majority of the side effec...
